Johnson & Johnson (JNJ) announced new data from the Phase 3 Vivacity-MG3 study and ongoing open label extension in a broad population of antibody-positive adults with generalized myasthenia gravis reinforcing the efficacy, sustained disease control and safety profile of IMAAVY. Through 120 weeks of follow-up, IMAAVY delivered sustained clinical improvements and reductions in total IgG in antibody-positive adult patients including anti-AChR+ and anti-MuSK+. Patients achieving sustained minimal symptom expression experienced greater improvements in quality of life than those with transient MSE in a post-hoc analysis of the Phase 3 study.
"As demonstrated in our pivotal trial, IMAAVY was shown to deliver sustained disease control in a broad population of people living with gMG, helping to address a critical unmet need," said Chris Gasink, Vice President, Medical Affairs, Autoantibody & Gastroenterology, Johnson & Johnson.
Johnson & Johnson previously announced plans to initiate EPIC in 2025. The study, comparing the efficacy of IMAAVY versus efgartigimod, is now enrolling participants.
In pre-market trading on NYSE, Johnson & Johnson shares are down 0.50 percent to $225.00.
For More Such Health News, visit rttnews.com.
For comments and feedback contact: editorial@rttnews.com
Business News
April 17, 2026 15:29 ET The ongoing conflict in the Middle East continues to raise concerns for policymakers who worry about the impact of the supply shock and high energy prices on the real economy. Producer price data and various survey results on the housing market were the main news from the U.S. this week. In Europe, industrial production data for the euro area gained attention. GDP figures out of China and the policy move by the Singapore central bank were in focus in Asia.